The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Bruce M. Psaty

Cardiovascular Health Research Unit

1730 Minor Ave

Suite 1360




Name/email consistency: high



  • Cardiovascular Health Research Unit, 1730 Minor Ave, Suite 1360, Seattle, USA. 2001 - 2010
  • Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, USA. 1999 - 2009


  1. Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture. Psaty, B.M. Circulation (2010) [Pubmed]
  2. Conflict of interest, disclosure, and trial reports. Psaty, B.M. JAMA (2009) [Pubmed]
  3. Variation in event rates in trials of patients with type 2 diabetes. Psaty, B.M., Prentice, R.L. JAMA (2009) [Pubmed]
  4. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Psaty, B.M., O'Donnell, C.J., Gudnason, V., Lunetta, K.L., Folsom, A.R., Rotter, J.I., Uitterlinden, A.G., Harris, T.B., Witteman, J.C., Boerwinkle, E. Circ. Cardiovasc. Genet (2009) [Pubmed]
  5. Clinical trial design and selected drug safety issues for antibiotics used to treat community-acquired pneumonia. Psaty, B.M. Clin. Infect. Dis. (2008) [Pubmed]
  6. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. Psaty, B.M., Kronmal, R.A. JAMA (2008) [Pubmed]
  7. Potential revisions to hypertension guidelines. Psaty, B.M. Am. J. Hypertens. (2008) [Pubmed]
  8. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. Psaty, B.M., Lumley, T. JAMA (2008) [Pubmed]
  9. FDA guidance on off-label promotion and the state of the literature from sponsors. Psaty, B.M., Ray, W. JAMA (2008) [Pubmed]
  10. Opportunities for enhancing the FDA guidance on pharmacovigilance. Psaty, B.M., Vandenbroucke, J.P. JAMA (2008) [Pubmed]
  11. Congress responds to the IOM drug safety report--in full. Psaty, B.M., Korn, D. JAMA (2007) [Pubmed]
  12. FDA responds to institute of medicine drug safety recommendations--in part. Psaty, B.M., Charo, R.A. JAMA (2007) [Pubmed]
  13. A new era of cardiovascular disease epidemiology. Psaty, B.M., Arnett, D., Burke, G. JAMA (2007) [Pubmed]
  14. Association between levels of blood pressure and measures of subclinical disease multi-ethnic study of atherosclerosis. Psaty, B.M., Arnold, A.M., Olson, J., Saad, M.F., Shea, S., Post, W., Burke, G.L. Am. J. Hypertens. (2006) [Pubmed]
  15. Contemplating ACTION--long-acting nifedipine in stable angina. Psaty, B.M., Furberg, C.D. Lancet (2004) [Pubmed]
  16. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. Psaty, B.M., Anderson, M., Kronmal, R.A., Tracy, R.P., Orchard, T., Fried, L.P., Lumley, T., Robbins, J., Burke, G., Newman, A.B., Furberg, C.D. J. Am. Geriatr. Soc (2004) [Pubmed]
  17. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. Psaty, B.M., Furberg, C.D., Ray, W.A., Weiss, N.S. JAMA (2004) [Pubmed]
  18. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. Psaty, B.M., Lumley, T., Furberg, C.D., Schellenbaum, G., Pahor, M., Alderman, M.H., Weiss, N.S. JAMA (2003) [Pubmed]
  19. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. Psaty, B.M., Smith, N.L., Heckbert, S.R., Vos, H.L., Lemaitre, R.N., Reiner, A.P., Siscovick, D.S., Bis, J., Lumley, T., Longstreth, W.T., Rosendaal, F.R. JAMA (2002) [Pubmed]
  20. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. Psaty, B.M., Smith, N.L., Lemaitre, R.N., Vos, H.L., Heckbert, S.R., LaCroix, A.Z., Rosendaal, F.R. JAMA (2001) [Pubmed]
  21. The potential costs of upcoding for heart failure in the United States. Psaty, B.M., Boineau, R., Kuller, L.H., Luepker, R.V. Am. J. Cardiol. (1999) [Pubmed]
WikiGenes - Universities